On Friday, Atyr Pharma Inc (NASDAQ: ATYR) was -3.99% drop from the session before settling in for the closing price of $3.26. A 52-week range for ATYR has been $1.42 – $4.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 429.49% over the past five years. When this article was written, the company’s average yearly earnings per share was at 17.86%. With a float of $86.00 million, this company’s outstanding shares have now reached $88.86 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -390.64%, operating margin of -28899.57%, and the pretax margin is -27243.4%.
Atyr Pharma Inc (ATYR) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Atyr Pharma Inc stocks. The insider ownership of Atyr Pharma Inc is 3.22%, while institutional ownership is 62.69%. The most recent insider transaction that took place on Mar 17 ’25, was worth 15,000. In this transaction Director of this company bought 3,750 shares at a rate of $4.00, taking the stock ownership to the 9,750 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Financial Officer sold 1,254 for $3.78, making the entire transaction worth $4,740. This insider now owns 31,763 shares in total.
Atyr Pharma Inc (ATYR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 17.86% per share during the next fiscal year.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
You can see what Atyr Pharma Inc (ATYR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1209.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Atyr Pharma Inc (NASDAQ: ATYR) saw its 5-day average volume 1.17 million, a negative change from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 4.79%. Additionally, its Average True Range was 0.31.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 21.74%, which indicates a significant increase from 11.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.82% in the past 14 days, which was higher than the 83.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.65, while its 200-day Moving Average is $2.74. Nevertheless, the first resistance level for the watch stands at $3.24 in the near term. At $3.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.43. If the price goes on to break the first support level at $3.05, it is likely to go to the next support level at $2.96. The third support level lies at $2.86 if the price breaches the second support level.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
There are 88,859K outstanding shares of the company, which has a market capitalization of 278.13 million. As of now, sales total 240 K while income totals -64,020 K. Its latest quarter income was 0 K while its last quarter net income were -14,970 K.
